SCHEMBL27428366

SCHEMBL27428366

CC(I)c1ccc2c(c1)C(=O)N(C(C)C)C2

nearest known ligand 0.38

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
MAP3K5 Q99683 1/20 0.38
THRB P10828 2/20 0.37
ALOX15 P16050 3/20 0.36
KDM4E B2RXH2 2/20 0.36
ALDH1A1 P00352 1/20 0.36
TSHR P16473 1/20 0.36
XIAP P98170 1/20 0.36
HKDC1 Q2TB90 1/20 0.36
HSD17B10 Q99714 1/20 0.36
TDP1 Q9NUW8 1/20 0.36
L3MBTL1 Q9Y468 1/20 0.36
PRF1 P14222 1/20 0.36
IDH1 O75874 1/20 0.36
SDCBP O00560 1/20 0.36
SDC2 P34741 1/20 0.36
KCNH2 Q12809 3/20 0.36
MEN1 O00255 3/20 0.35
KMT2A Q03164 3/20 0.35
MAPT P10636 1/20 0.34
SMN1; SMN2 Q16637 1/20 0.34

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL24109490 0.87 HSD17B10 (0.44) MAP3K5THRBALOX15KDM4EALDH1A1
SCHEMBL17517151 0.79 MAP3K5 (0.42) MAP3K5THRBKCNH2LMNA
SCHEMBL18086772 0.78 SDCBP (0.45) MAP3K5THRBTDP1L3MBTL1SDCBP
SCHEMBL21939317 0.78 ALDH1A1 (0.44) MAP3K5THRBALOX15KDM4EALDH1A1
SCHEMBL18086765 0.78 KCNH2 (0.48) MAP3K5THRBTDP1KCNH2MAPT
SCHEMBL18591660 0.78 SDCBP (0.45) MAP3K5SDCBPSDC2KCNH2MEN1
SCHEMBL13322654 0.75 LMNA (0.42) MAP3K5THRBALOX15KDM4EPRF1
SCHEMBL14084763 0.75 MEN1 (0.45) MAP3K5ALOX15KDM4EALDH1A1TDP1
SCHEMBL13015321 0.75 ALDH1A1 (0.48) KDM4EALDH1A1L3MBTL1KCNH2MEN1
SCHEMBL14072400 0.75 NPC1 (0.44) MAP3K5THRBALOX15ALDH1A1L3MBTL1

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 1 patent. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-20240217972-A1 GLUTARIMIDE-CONTAINING PAN-KRAS-MUTANT DEGRADER COMPOUNDS AND USES THEREOF TIGER BIOTHERAPEUTICS INC. 2024-07-04 US disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20240217972-A1 GLUTARIMIDE-CONTAINING PAN-KRAS-MUTANT DEGRADER COMPOUNDS AND USES THEREOF KRAS, VHL, HRAS MAP3K5 1940/4885THRB 4099/4885ALOX15 3752/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.